A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
1970/03/01 by G. M. Simpson, G. M. SIMPSON, M. B. +6 · 36 citations
Medicine · #Pharmaceutical Practices and Patient Outcomes
paper · doi:10.1111/j.1600-0447.1970.tb02066.x
Abstract
SUMMARY A modification of an earlier rating scale for extrapyramidal system disturbance is described, and evidence for the validity and reliability of the scale is presented. The usefulness of the scale in studies of neuroleptic drugs is discussed. By its application it is possible to quantify extrapyramidal side effects and to separate them into four principal factors.
Cited by
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
- A Rating Scale for Drug-Induced Akathisia
- Social deprivation in schizophrenia spectrum disorders: A systematic review
- Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study
- Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review
- Association between depressive symptoms, CRP and metabolism-related indicators in Han Chinese patients with chronic schizophrenia
- Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial
- A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
- Schizophrenia Following Early Adolescence Prodrome: A Neurodevelopmental Subtype With Autism-like Sensorimotor and Social Cognition Deficits
- Olanzapine
- Altered Modularity and Disproportional Integration in Functional Networks are Markers of Abnormal Brain Organization in Schizophrenia
- The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. [europepmc]
- The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. [europepmc]
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. [europepmc]
- Initial phase 2 trial of a nicotinic agonist in schizophrenia. [europepmc]
- Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. [europepmc]
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. [europepmc]
- A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). [europepmc]
- 1H-MRS at 4 tesla in minimally treated early schizophrenia. [europepmc]
- Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. [europepmc]
- Olanzapine versus other atypical antipsychotics for schizophrenia. [europepmc]
- High dose D-serine in the treatment of schizophrenia. [europepmc]
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. [europepmc]
- Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. [europepmc]
- Effectiveness of switching from antipsychotic polypharmacy to monotherapy. [europepmc]
- A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [europepmc]
- The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. [europepmc]
- The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia. [europepmc]
- Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. [europepmc]
- Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. [europepmc]
- The Function Biomedical Informatics Research Network Data Repository. [europepmc]
- Multimodal Neuroimaging in Schizophrenia: Description and Dissemination. [europepmc]
- Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. [europepmc]
- The clinical characterization of the patient with primary psychosis aimed at personalization of management. [europepmc]
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. [europepmc]
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. [europepmc]
Related